25 XP   0   0   10

Combigene AB
Buy, Hold or Sell?

Let's analyse Combigene together

PenkeI guess you are interested in Combigene AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Combigene AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Combigene AB

I send you an email if I find something interesting about Combigene AB.

Quick analysis of Combigene (30 sec.)










What can you expect buying and holding a share of Combigene? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr5.88
Expected worth in 1 year
kr4.08
How sure are you?
42.3%

+ What do you gain per year?

Total Gains per Share
kr-1.80
Return On Investment
-50.5%

For what price can you sell your share?

Current Price per Share
kr3.57
Expected price per share
kr3.15 - kr5.75
How sure are you?
50%

1. Valuation of Combigene (5 min.)




Live pricePrice per Share (EOD)

kr3.57

Intrinsic Value Per Share

kr3.45 - kr4.61

Total Value Per Share

kr9.33 - kr10.49

2. Growth of Combigene (5 min.)




Is Combigene growing?

Current yearPrevious yearGrowGrow %
How rich?$10.9m$14.8m-$2.9m-24.4%

How much money is Combigene making?

Current yearPrevious yearGrowGrow %
Making money-$838.1k-$144.6k-$693.4k-82.7%
Net Profit Margin-703.5%44.0%--

How much money comes from the company's main activities?

3. Financial Health of Combigene (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#678 / 1031

Most Revenue
#615 / 1031

Most Profit
#237 / 1031

Most Efficient
#790 / 1031

What can you expect buying and holding a share of Combigene? (5 min.)

Welcome investor! Combigene's management wants to use your money to grow the business. In return you get a share of Combigene.

What can you expect buying and holding a share of Combigene?

First you should know what it really means to hold a share of Combigene. And how you can make/lose money.

Speculation

The Price per Share of Combigene is kr3.57. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Combigene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Combigene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr5.88. Based on the TTM, the Book Value Change Per Share is kr-0.45 per quarter. Based on the YOY, the Book Value Change Per Share is kr0.95 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Combigene.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.03-0.8%-0.04-1.2%-0.01-0.2%-0.02-0.6%-0.02-0.6%
Usd Book Value Change Per Share-0.03-0.8%-0.04-1.2%0.092.5%0.020.6%0.020.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.03-0.8%-0.04-1.2%0.092.5%0.020.6%0.020.6%
Usd Price Per Share0.25-0.53-0.82-0.43-0.36-
Price to Earnings Ratio-2.09--3.37--1.08--1.52--0.41-
Price-to-Total Gains Ratio-8.37--13.46-15.16--1.57-9.08-
Price to Book Ratio0.46-0.87-1.10-1.00-1.46-
Price-to-Total Gains Ratio-8.37--13.46-15.16--1.57-9.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.33558
Number of shares2979
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.040.02
Usd Total Gains Per Share-0.040.02
Gains per Quarter (2979 shares)-126.1067.88
Gains per Year (2979 shares)-504.39271.53
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-504-5140272262
20-1009-10180543534
30-1513-15220815806
40-2018-2026010861078
50-2522-2530013581350
60-3026-3034016291622
70-3531-3538019011894
80-4035-4042021722166
90-4539-4546024442438
100-5044-5050027152710

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%3.09.00.025.0%3.017.00.015.0%4.022.00.015.4%4.022.00.015.4%
Book Value Change Per Share0.04.00.00.0%4.08.00.033.3%8.012.00.040.0%11.014.01.042.3%11.014.01.042.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.026.00.0%0.00.026.00.0%
Total Gains per Share0.04.00.00.0%4.08.00.033.3%8.012.00.040.0%11.014.01.042.3%11.014.01.042.3%

Fundamentals of Combigene

About Combigene AB

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.

Fundamental data was last updated by Penke on 2024-03-08 17:56:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Combigene AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Combigene earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Combigene to the Biotechnology industry mean.
  • A Net Profit Margin of -1,067.1% means that kr-10.67 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Combigene AB:

  • The MRQ is -1,067.1%. The company is making a huge loss. -2
  • The TTM is -703.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,067.1%TTM-703.5%-363.6%
TTM-703.5%YOY44.0%-747.5%
TTM-703.5%5Y-128.5%-575.1%
5Y-128.5%10Y-86,121.4%+85,992.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,067.1%-159.2%-907.9%
TTM-703.5%-202.3%-501.2%
YOY44.0%-263.0%+307.0%
5Y-128.5%-452.4%+323.9%
10Y-86,121.4%-589.0%-85,532.4%
1.1.2. Return on Assets

Shows how efficient Combigene is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Combigene to the Biotechnology industry mean.
  • -5.3% Return on Assets means that Combigene generated kr-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Combigene AB:

  • The MRQ is -5.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.3%TTM-6.6%+1.4%
TTM-6.6%YOY-1.0%-5.6%
TTM-6.6%5Y-6.9%+0.2%
5Y-6.9%10Y-10.1%+3.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.3%-12.5%+7.2%
TTM-6.6%-12.2%+5.6%
YOY-1.0%-11.2%+10.2%
5Y-6.9%-13.3%+6.4%
10Y-10.1%-14.6%+4.5%
1.1.3. Return on Equity

Shows how efficient Combigene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Combigene to the Biotechnology industry mean.
  • -5.5% Return on Equity means Combigene generated kr-0.05 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Combigene AB:

  • The MRQ is -5.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.5%TTM-6.9%+1.5%
TTM-6.9%YOY-1.1%-5.8%
TTM-6.9%5Y-12.1%+5.1%
5Y-12.1%10Y-15.8%+3.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.5%-16.0%+10.5%
TTM-6.9%-15.8%+8.9%
YOY-1.1%-13.9%+12.8%
5Y-12.1%-18.2%+6.1%
10Y-15.8%-19.1%+3.3%

1.2. Operating Efficiency of Combigene AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Combigene is operating .

  • Measures how much profit Combigene makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Combigene to the Biotechnology industry mean.
  • An Operating Margin of -1,492.1% means the company generated kr-14.92  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Combigene AB:

  • The MRQ is -1,492.1%. The company is operating very inefficient. -2
  • The TTM is -809.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,492.1%TTM-809.7%-682.4%
TTM-809.7%YOY44.0%-853.7%
TTM-809.7%5Y-149.7%-660.0%
5Y-149.7%10Y-115.2%-34.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,492.1%-299.5%-1,192.6%
TTM-809.7%-208.5%-601.2%
YOY44.0%-280.2%+324.2%
5Y-149.7%-459.9%+310.2%
10Y-115.2%-596.9%+481.7%
1.2.2. Operating Ratio

Measures how efficient Combigene is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 15.92 means that the operating costs are kr15.92 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Combigene AB:

  • The MRQ is 15.921. The company is inefficient in keeping operating costs low. -1
  • The TTM is 14.284. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ15.921TTM14.284+1.637
TTM14.284YOY0.159+14.125
TTM14.2845Y2.905+11.379
5Y2.90510Y857.468-854.563
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.9212.817+13.104
TTM14.2843.181+11.103
YOY0.1593.609-3.450
5Y2.9055.554-2.649
10Y857.4687.396+850.072

1.3. Liquidity of Combigene AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Combigene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 24.84 means the company has kr24.84 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Combigene AB:

  • The MRQ is 24.841. The company is very able to pay all its short-term debts. +2
  • The TTM is 21.350. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ24.841TTM21.350+3.491
TTM21.350YOY23.666-2.316
TTM21.3505Y13.202+8.148
5Y13.20210Y10.822+2.380
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ24.8413.987+20.854
TTM21.3504.440+16.910
YOY23.6665.569+18.097
5Y13.2026.158+7.044
10Y10.8226.492+4.330
1.3.2. Quick Ratio

Measures if Combigene is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Combigene to the Biotechnology industry mean.
  • A Quick Ratio of 24.84 means the company can pay off kr24.84 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Combigene AB:

  • The MRQ is 24.841. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 21.356. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ24.841TTM21.356+3.485
TTM21.356YOY22.832-1.476
TTM21.3565Y12.945+8.411
5Y12.94510Y10.436+2.509
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ24.8413.653+21.188
TTM21.3564.158+17.198
YOY22.8325.515+17.317
5Y12.9456.012+6.933
10Y10.4366.206+4.230

1.4. Solvency of Combigene AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Combigene assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Combigene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.03 means that Combigene assets are financed with 3.4% credit (debt) and the remaining percentage (100% - 3.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Combigene AB:

  • The MRQ is 0.034. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.041. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.034TTM0.041-0.007
TTM0.041YOY0.037+0.004
TTM0.0415Y0.165-0.124
5Y0.16510Y0.186-0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0340.336-0.302
TTM0.0410.330-0.289
YOY0.0370.267-0.230
5Y0.1650.367-0.202
10Y0.1860.378-0.192
1.4.2. Debt to Equity Ratio

Measures if Combigene is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Combigene to the Biotechnology industry mean.
  • A Debt to Equity ratio of 3.6% means that company has kr0.04 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Combigene AB:

  • The MRQ is 0.036. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.043. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.036TTM0.043-0.007
TTM0.043YOY0.039+0.004
TTM0.0435Y0.329-0.286
5Y0.32910Y0.354-0.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0360.376-0.340
TTM0.0430.398-0.355
YOY0.0390.334-0.295
5Y0.3290.431-0.102
10Y0.3540.476-0.122

2. Market Valuation of Combigene AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Combigene generates.

  • Above 15 is considered overpriced but always compare Combigene to the Biotechnology industry mean.
  • A PE ratio of -2.09 means the investor is paying kr-2.09 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Combigene AB:

  • The EOD is -2.779. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.094. Based on the earnings, the company is expensive. -2
  • The TTM is -3.365. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.779MRQ-2.094-0.685
MRQ-2.094TTM-3.365+1.272
TTM-3.365YOY-1.083-2.282
TTM-3.3655Y-1.523-1.843
5Y-1.52310Y-0.409-1.114
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.779-2.697-0.082
MRQ-2.094-2.422+0.328
TTM-3.365-2.709-0.656
YOY-1.083-4.116+3.033
5Y-1.523-6.257+4.734
10Y-0.409-6.478+6.069
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Combigene AB:

  • The EOD is -2.525. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.903. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.768. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.525MRQ-1.903-0.623
MRQ-1.903TTM-3.768+1.865
TTM-3.768YOY25.335-29.103
TTM-3.7685Y4.017-7.785
5Y4.01710Y2.466+1.552
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.525-3.344+0.819
MRQ-1.903-2.939+1.036
TTM-3.768-3.486-0.282
YOY25.335-5.592+30.927
5Y4.017-8.464+12.481
10Y2.466-8.872+11.338
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Combigene is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.46 means the investor is paying kr0.46 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Combigene AB:

  • The EOD is 0.607. Based on the equity, the company is cheap. +2
  • The MRQ is 0.457. Based on the equity, the company is cheap. +2
  • The TTM is 0.872. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.607MRQ0.457+0.150
MRQ0.457TTM0.872-0.414
TTM0.872YOY1.098-0.226
TTM0.8725Y0.999-0.128
5Y0.99910Y1.463-0.464
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6072.198-1.591
MRQ0.4572.042-1.585
TTM0.8722.121-1.249
YOY1.0982.907-1.809
5Y0.9993.682-2.683
10Y1.4634.114-2.651
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Combigene AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.321-0.450+40%0.946-134%0.242-233%0.226-242%
Book Value Per Share--5.8816.414-8%7.978-26%4.407+33%3.510+68%
Current Ratio--24.84121.350+16%23.666+5%13.202+88%10.822+130%
Debt To Asset Ratio--0.0340.041-16%0.037-8%0.165-79%0.186-82%
Debt To Equity Ratio--0.0360.043-17%0.039-8%0.329-89%0.354-90%
Dividend Per Share----0%-0%-0%-0%
Eps---0.321-0.450+40%-0.078-76%-0.245-24%-0.220-31%
Free Cash Flow Per Share---0.353-0.386+9%-0.210-40%-0.306-13%-0.246-30%
Free Cash Flow To Equity Per Share---0.353-0.388+10%-0.210-40%0.232-252%0.243-246%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--4.610--------
Intrinsic Value_10Y_min--3.449--------
Intrinsic Value_1Y_max---0.817--------
Intrinsic Value_1Y_min---0.803--------
Intrinsic Value_3Y_max---1.480--------
Intrinsic Value_3Y_min---1.433--------
Intrinsic Value_5Y_max---0.968--------
Intrinsic Value_5Y_min---0.982--------
Market Cap70690284.000+25%53265228.000112322307.000-53%172913979.000-69%101751407.676-48%85362570.328-38%
Net Profit Margin---10.671-7.035-34%0.440-2526%-1.285-88%-861.214+7970%
Operating Margin---14.921-8.097-46%0.440-3492%-1.497-90%-1.152-92%
Operating Ratio--15.92114.284+11%0.159+9887%2.905+448%857.468-98%
Pb Ratio0.607+25%0.4570.872-48%1.098-58%0.999-54%1.463-69%
Pe Ratio-2.779-33%-2.094-3.365+61%-1.083-48%-1.523-27%-0.409-80%
Price Per Share3.570+25%2.6905.673-53%8.733-69%4.540-41%3.850-30%
Price To Free Cash Flow Ratio-2.525-33%-1.903-3.768+98%25.335-108%4.017-147%2.466-177%
Price To Total Gains Ratio-11.113-33%-8.374-13.462+61%15.163-155%-1.567-81%9.080-192%
Quick Ratio--24.84121.356+16%22.832+9%12.945+92%10.436+138%
Return On Assets---0.053-0.066+26%-0.010-80%-0.069+30%-0.101+91%
Return On Equity---0.055-0.069+27%-0.011-80%-0.121+121%-0.158+190%
Total Gains Per Share---0.321-0.450+40%0.946-134%0.242-233%0.226-242%
Usd Book Value--10946864.09411937953.024-8%14849464.397-26%8583871.141+28%6825563.536+60%
Usd Book Value Change Per Share---0.030-0.042+40%0.089-134%0.023-233%0.021-242%
Usd Book Value Per Share--0.5530.603-8%0.750-26%0.414+33%0.330+68%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.030-0.042+40%-0.007-76%-0.023-24%-0.021-31%
Usd Free Cash Flow---657812.000-718089.500+9%-391643.551-40%-400263.891-39%-327776.500-50%
Usd Free Cash Flow Per Share---0.033-0.036+9%-0.020-40%-0.029-13%-0.023-30%
Usd Free Cash Flow To Equity Per Share---0.033-0.036+10%-0.020-40%0.022-252%0.023-246%
Usd Market Cap6644886.696+25%5006931.43210558296.858-53%16253914.026-69%9564632.322-48%8024081.611-38%
Usd Price Per Share0.336+25%0.2530.533-53%0.821-69%0.427-41%0.362-30%
Usd Profit---597840.000-838151.000+40%-144680.406-76%-318865.677-47%-303811.478-49%
Usd Revenue--56024.000134349.500-58%322708.627-83%486407.009-88%385034.843-85%
Usd Total Gains Per Share---0.030-0.042+40%0.089-134%0.023-233%0.021-242%
 EOD+5 -3MRQTTM+21 -12YOY+8 -255Y+13 -2010Y+15 -18

3.2. Fundamental Score

Let's check the fundamental score of Combigene AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.779
Price to Book Ratio (EOD)Between0-10.607
Net Profit Margin (MRQ)Greater than0-10.671
Operating Margin (MRQ)Greater than0-14.921
Quick Ratio (MRQ)Greater than124.841
Current Ratio (MRQ)Greater than124.841
Debt to Asset Ratio (MRQ)Less than10.034
Debt to Equity Ratio (MRQ)Less than10.036
Return on Equity (MRQ)Greater than0.15-0.055
Return on Assets (MRQ)Greater than0.05-0.053
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Combigene AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.004
Ma 20Greater thanMa 503.710
Ma 50Greater thanMa 1003.451
Ma 100Greater thanMa 2003.069
OpenGreater thanClose3.610
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets120,612
Total Liabilities4,156
Total Stockholder Equity116,457
 As reported
Total Liabilities 4,156
Total Stockholder Equity+ 116,457
Total Assets = 120,612

Assets

Total Assets120,612
Total Current Assets103,239
Long-term Assets17,373
Total Current Assets
Cash And Cash Equivalents 101,440
Net Receivables 1,799
Total Current Assets  (as reported)103,239
Total Current Assets  (calculated)103,239
+/-0
Long-term Assets
Property Plant Equipment 851
Long-term Assets Other 16,517
Long-term Assets  (as reported)17,373
Long-term Assets  (calculated)17,368
+/- 5

Liabilities & Shareholders' Equity

Total Current Liabilities4,156
Long-term Liabilities0
Total Stockholder Equity116,457
Total Current Liabilities
Other Current Liabilities 4,156
Total Current Liabilities  (as reported)4,156
Total Current Liabilities  (calculated)4,156
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock990
Retained Earnings -108,657
Other Stockholders Equity 224,124
Total Stockholder Equity (as reported)116,457
Total Stockholder Equity (calculated)116,457
+/-0
Other
Cash and Short Term Investments 101,440
Common Stock Shares Outstanding 19,801
Liabilities and Stockholders Equity 120,612
Net Debt -101,440
Net Working Capital 99,083



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
> Total Assets 
0
0
0
8,139
7,776
5,688
51,547
35,116
30,744
25,619
32,926
43,818
38,325
46,561
68,796
79,414
68,943
115,063
105,692
166,221
162,554
165,499
170,200
158,221
143,330
137,638
128,248
120,612
120,612128,248137,638143,330158,221170,200165,499162,554166,221105,692115,06368,94379,41468,79646,56138,32543,81832,92625,61930,74435,11651,5475,6887,7768,139000
   > Total Current Assets 
0
0
0
6,915
6,552
4,464
49,989
33,462
28,995
23,778
8,898
18,882
14,000
22,847
44,102
55,368
45,546
92,315
83,445
144,622
141,604
145,197
150,548
139,217
124,866
119,818
111,076
103,239
103,239111,076119,818124,866139,217150,548145,197141,604144,62283,44592,31545,54655,36844,10222,84714,00018,8828,89823,77828,99533,46249,9894,4646,5526,915000
       Cash And Cash Equivalents 
0
0
0
4,918
4,604
3,561
16,569
31,805
28,228
21,839
3,785
13,166
9,545
18,026
35,245
48,895
34,091
82,376
66,087
136,744
121,665
125,953
144,940
131,777
120,506
115,442
107,187
101,440
101,440107,187115,442120,506131,777144,940125,953121,665136,74466,08782,37634,09148,89535,24518,0269,54513,1663,78521,83928,22831,80516,5693,5614,6044,918000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
5,113
500
4,455
4,822
7,210
958
10,631
9,115
16,534
7,464
6,826
11,989
5,608
6,811
4,359
4,544
3,889
1,799
1,7993,8894,5444,3596,8115,60811,9896,8267,46416,5349,11510,6319587,2104,8224,4555005,1130000000000
       Other Current Assets 
0
0
0
1,997
1,948
903
33,420
1,657
767
1,939
5,113
5,716
4,455
4,821
7,209
5,649
10,631
9,115
16,534
7,879
-1
-1
5,608
629
1
-168
0
0
00-16816295,608-1-17,87916,5349,11510,6315,6497,2094,8214,4555,7165,1131,9397671,65733,4209031,9481,997000
   > Long-term Assets 
0
0
0
1,224
1,224
1,224
1,558
1,654
1,750
1,842
24,029
24,936
24,325
23,714
24,694
24,046
23,397
22,748
22,247
21,599
20,950
20,301
19,652
19,004
18,464
17,820
17,171
17,373
17,37317,17117,82018,46419,00419,65220,30120,95021,59922,24722,74823,39724,04624,69423,71424,32524,93624,0291,8421,7501,6541,5581,2241,2241,224000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
851
851000000000000000000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
21,801
0
0
0
19,506
0
0
0
17,211
0
0
0
14,916
0
0
0
0
000014,91600017,21100019,50600021,80100000000000
       Intangible Assets 
0
0
0
1,224
1,224
1,224
1,558
1,654
0
0
24,029
3,135
24,325
23,714
24,694
4,540
23,397
22,748
22,247
4,387
20,950
20,301
19,652
4,087
18,464
17,815
0
0
0017,81518,4644,08719,65220,30120,9504,38722,24722,74823,3974,54024,69423,71424,3253,13524,029001,6541,5581,2241,2241,224000
       Other Assets 
0
0
0
0
0
0
0
0
0
-1
-1
49,872
0
-1
-1
0
0
0
0
0
0
1
0
0
0
5
1
0
0150001000000-1-1049,872-1-1000000000
> Total Liabilities 
0
0
0
1,627
1,174
1,304
27,934
14,661
12,761
10,450
5,026
23,514
25,690
13,512
11,547
7,981
8,366
4,007
4,861
7,942
6,959
5,388
6,136
6,099
5,825
6,418
5,431
4,156
4,1565,4316,4185,8256,0996,1365,3886,9597,9424,8614,0078,3667,98111,54713,51225,69023,5145,02610,45012,76114,66127,9341,3041,1741,627000
   > Total Current Liabilities 
0
0
0
1,627
1,174
1,304
27,933
14,661
12,760
10,450
5,027
23,514
25,689
13,513
11,547
7,981
8,366
4,007
4,861
7,942
6,959
5,387
6,136
6,099
5,824
6,419
5,431
4,156
4,1565,4316,4195,8246,0996,1365,3876,9597,9424,8614,0078,3667,98111,54713,51325,68923,5145,02710,45012,76014,66127,9331,3041,1741,627000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
7,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000007,00000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
7,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000007,00000000000000
       Accounts payable 
0
0
0
513
0
0
0
1,457
0
0
0
2,135
0
0
0
2,995
0
0
0
3,377
0
0
0
1,788
0
0
0
0
00001,7880003,3770002,9950002,1350001,457000513000
       Other Current Liabilities 
0
0
0
1,114
1,174
1,304
27,933
13,204
12,760
10,450
5,027
14,379
25,689
13,513
11,547
4,986
8,366
4,007
4,861
4,565
6,959
5,387
6,136
4,310
5,824
6,419
5,431
4,156
4,1565,4316,4195,8244,3106,1365,3876,9594,5654,8614,0078,3664,98611,54713,51325,68914,3795,02710,45012,76013,20427,9331,3041,1741,114000
   > Long-term Liabilities 
0
0
0
0
0
0
1
0
1
-1
-1
0
1
-1
0
0
0
0
0
3,377
0
1
0
0
1
-1
0
0
00-1100103,37700000-110-1-1101000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
-1
0
1
-1
0
0
0
0
0
0
0
1
0
0
0
-1
0
0
00-100010000000-110-10000000000
> Total Stockholder Equity
0
0
0
6,512
6,602
4,384
23,613
20,455
17,983
15,169
26,081
18,465
10,877
31,377
57,249
71,433
60,577
111,056
100,831
158,279
155,595
160,111
164,064
152,122
137,505
131,220
122,817
116,457
116,457122,817131,220137,505152,122164,064160,111155,595158,279100,831111,05660,57771,43357,24931,37710,87718,46526,08115,16917,98320,45523,6134,3846,6026,512000
   Common Stock
0
0
0
1,652
1,652
1,720
1,720
5,159
5,159
5,159
6,372
6,505
6,505
12,562
17,822
22,928
22,928
39,602
990
990
990
990
990
990
990
990
990
990
99099099099099099099099099099039,60222,92822,92817,82212,5626,5056,5056,3725,1595,1595,1591,7201,7201,6521,652000
   Retained Earnings Total Equity0000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
68,941
69,348
88,094
116,263
136,305
136,305
185,512
224,124
224,124
224,124
224,124
224,124
224,124
224,124
224,124
0
0
00224,124224,124224,124224,124224,124224,124224,124224,124185,512136,305136,305116,26388,09469,34868,94100000000000
   Treasury Stock0000000000000000000000000000
   Other Stockholders Equity 
0
0
0
13,818
6,949
6,822
31,880
54,590
15,295
15,295
28,433
68,941
11,955
30,701
57,845
48,505
48,505
97,712
136,324
157,289
157,289
157,289
157,289
224,124
151,132
151,133
151,132
224,124
224,124151,132151,133151,132224,124157,289157,289157,289157,289136,32497,71248,50548,50557,84530,70111,95568,94128,43315,29515,29554,59031,8806,8226,94913,818000



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue5,544
Cost of Revenue-44,327
Gross Profit-38,783-38,783
 
Operating Income (+$)
Gross Profit-38,783
Operating Expense-65,339
Operating Income-38,783-104,122
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense65,3390
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-786
Net Interest Income786
 
Pretax Income (+$)
Operating Income-38,783
Net Interest Income786
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-35,665-41,901
EBIT - interestExpense = -38,783
-35,665
-35,665
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-38,783-35,665
Earnings Before Interest and Taxes (EBITDA)-36,159
 
After tax Income (+$)
Income Before Tax-35,665
Tax Provision-0
Net Income From Continuing Ops-41,247-35,665
Net Income-35,665
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses44,327
Total Other Income/Expenses Net3,118-786
 

Technical Analysis of Combigene
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Combigene. The general trend of Combigene is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Combigene's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Combigene AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4 < 4 < 5.75.

The bearish price targets are: 3.28 > 3.165 > 3.15.

Tweet this
Combigene AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Combigene AB. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Combigene AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Combigene AB. The current macd is 0.06786416.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Combigene price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Combigene. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Combigene price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Combigene AB Daily Moving Average Convergence/Divergence (MACD) ChartCombigene AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Combigene AB. The current adx is 41.37.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Combigene shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Combigene AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Combigene AB. The current sar is 3.44630388.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Combigene AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Combigene AB. The current rsi is 47.00. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Combigene AB Daily Relative Strength Index (RSI) ChartCombigene AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Combigene AB. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Combigene price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Combigene AB Daily Stochastic Oscillator ChartCombigene AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Combigene AB. The current cci is -81.64452633.

Combigene AB Daily Commodity Channel Index (CCI) ChartCombigene AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Combigene AB. The current cmo is -20.95211963.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Combigene AB Daily Chande Momentum Oscillator (CMO) ChartCombigene AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Combigene AB. The current willr is -86.86868687.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Combigene AB Daily Williams %R ChartCombigene AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Combigene AB.

Combigene AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Combigene AB. The current atr is 0.22929539.

Combigene AB Daily Average True Range (ATR) ChartCombigene AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Combigene AB. The current obv is -1,757,769.

Combigene AB Daily On-Balance Volume (OBV) ChartCombigene AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Combigene AB. The current mfi is 40.44.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Combigene AB Daily Money Flow Index (MFI) ChartCombigene AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Combigene AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Combigene AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Combigene AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.004
Ma 20Greater thanMa 503.710
Ma 50Greater thanMa 1003.451
Ma 100Greater thanMa 2003.069
OpenGreater thanClose3.610
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Combigene with someone you think should read this too:
  • Are you bullish or bearish on Combigene? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Combigene? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Combigene AB

I send you an email if I find something interesting about Combigene AB.


Comments

How you think about this?

Leave a comment

Stay informed about Combigene AB.

Receive notifications about Combigene AB in your mailbox!